Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Liabilities and Shareholders Equity: 2019-2023

Historic Liabilities and Shareholders Equity for ADC Therapeutics (ADCT) over the last 3 years, with Sep 2023 value amounting to $466.9 million.

  • ADC Therapeutics' Liabilities and Shareholders Equity fell 12.20% to $466.9 million in Q3 2023 from the same period last year, while for Sep 2023 it was $1.9 billion, marking a year-over-year increase of 18.23%. This contributed to the annual value of $490.9 million for FY2022, which is 79330.62% up from last year.
  • According to the latest figures from Q3 2023, ADC Therapeutics' Liabilities and Shareholders Equity is $466.9 million, which was down 7.96% from $507.3 million recorded in Q2 2023.
  • In the past 5 years, ADC Therapeutics' Liabilities and Shareholders Equity registered a high of $638.0 million during Q3 2021, and its lowest value of $137,682 during Q4 2019.
  • Its 3-year average for Liabilities and Shareholders Equity is $466.5 million, with a median of $490.9 million in 2022.
  • As far as peak fluctuations go, ADC Therapeutics' Liabilities and Shareholders Equity skyrocketed by 124,119.86% in 2021, and later fell by 19.63% in 2023.
  • Over the past 5 years, ADC Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $137,682 in 2019, then reached $521,526 in 2020, then spiked by 122,229.28% to $617,972 in 2021, then soared by 79,330.62% to $490.9 million in 2022, then dropped by 12.20% to $466.9 million in 2023.
  • Its Liabilities and Shareholders Equity stands at $466.9 million for Q3 2023, versus $507.3 million for Q2 2023 and $467.7 million for Q1 2023.